Details About Generic Salt ::  Oral

Main Medicine Class:: Hormone,contraceptive   

Alesse, Brevicon, Demulen 1/35, Demulen 1/50, Desogen, Estrostep 21, Estrostep Fe, Jenest-28, Levlen, Levlite, Levora 0.15/30, Loestrin 21 1/20, Loestrin 21 1.5/30, Loestrin Fe 1/20, Loestrin Fe 1.5/30, Lo/Ovral, Mircette, ModiCon, Necon 0.5/35, Necon 1/35, Necon 1/50, Necon 10/11, Nelova 0.5/35 E, Nelova 1/35 E, Nelova 1/50 M, Nelova 10/11, Nordette, Norinyl 1 + 35, Norinyl 1 + 50, Ortho-Cept, Ortho-Cyclen, Ortho-Novum 1/50, Ortho-Novum 1/35, Ortho-Novum 7/7/7, Ortho-Novum 10/11, Ortho Tri-Cyclen, Ovcon-35, Ovcon-50, Ovral-28, Tri-Levelen, Tri-Norinyl, Triphasil, Trivora-28, Zovia 1/35E, Zovia 1/50E

Class: Hormone/contraceptive

Drugs Class ::

 Action Inhibits ovulation by suppressing gonadotropins, follicle-stimulating hormone and luteinizing hormone.

Indications for Drugs ::

 Indications Prevention of pregnancy. Unlabeled use(s): Postcoital contraceptive.

Drug Dose ::

 Route/Dosage

SUNDAY-START PACKAGING

ADULTS: PO 1 tablet daily beginning on first Sunday after menstruation begins. If menstruation begins on Sunday, take first tablet on that day.

21-DAY REGIMEN

ADULTS: PO 1 tablet daily for 21 days, beginning on day 5 of cycle. Take no tablets for 7 days; then start new course of 21-day regimen.

28-DAY REGIMEN

ADULTS: PO 1 tablet daily.

Contraindication ::

 Contraindications Thrombophlebitis; thromboembolic disorders; history of deep vein thrombophlebitis; cerebral vascular disease; MI; coronary artery disease; known or suspected breast carcinoma or estrogen-dependent neoplasia; past or present benign or malignant liver tumors that developed during use of estrogen-containing products; past or present angina pectoris; undiagnosed abnormal genital bleeding; known or suspected pregnancy; cholestatic jaundice of pregnancy or jaundice with prior pill use.

Drug Precautions ::

 Precautions

Pregnancy: Category X. Lactation: Excreted in breast milk. Defer use until infant weaned. Acute intermittent porphyria: May be precipitated by estrogen therapy in susceptible individuals. Carbohydrate and lipid metabolism: Glucose tolerance may decrease; triglycerides and total phospholipids may increase. Progestins may elevate LDL levels. Depression: Use drug with caution in patients with history of depression. Fibroids: Oral contraceptives may cause an increase in size of preexisting uterine leiomyomata (fibroids). Fluid retention: Use drug with caution in patients with hypertension, convulsive disorders, migraines, asthma, cardiac, hepatic or renal dysfunction. Liver dysfunction: May impair metabolism of oral contraceptives. Pyridoxine deficiency: May occur due to disturbance in normal tryptophan metabolism. Serum folate: May be depressed by oral contraceptive therapy. Tartrazine sensitivity: Some products may contain tartrazine, which may cause allergic-type reaction in susceptible individuals.

Drug Side Effects ::

 Adverse Reactions

CV: Coronary thrombosis; MI; hypertension. CNS: Cerebral thrombosis; cerebral hemorrhage; migraine; mental depression. DERM: Melasma; rash; photosensitivity. EENT: Steepening of corneal curvature; contact lens intolerance. GI: Nausea and vomiting; abdominal cramps; bloating; mesenteric thrombosis. GU: Renal artery thrombosis; break-through bleeding; spotting; change in menstrual flow; dysmenorrhea; amenorrhea; temporary infertility after discontinuation; change in cervical erosion and cervical secretions; endocervical hyperplasia; increase in size of uterine leiomyomata; vaginal candidiasis. HEMA: Thrombophlebitis and thrombosis; arterial thromboembolism. HEPA: Cholestatic jaundice; gallbladder disease. RESP: Pulmonary embolism. OTHER: Raynaud’s disease; congenital anomalies; liver tumors; hepatocellular carcinoma; breast tenderness, enlargement, secretion, diminished lactation; edema; weight change; reduced carbohydrate tolerance; prolactin-secreting pituitary tumors; increased prevalence of cervical chlamydia trachomatous.

Drug Mode of Action ::  

 Action Inhibits ovulation by suppressing gonadotropins, follicle-stimulating hormone and luteinizing hormone.

Drug Interactions ::

 Interactions

Barbiturates, hydantoins, rifampin, griseofulvin, penicillin, tetracyclines: Decreased effectiveness of oral contraceptive. Use additional form of birth control during concomitant therapy. Benzodiazepines: Increased benzodiazepine therapeutic effect or toxicity. Caffeine: Increased caffeine therapeutic effect or toxicity. Corticosteroids: Increased corticosteroid effect or toxicity. Metoprolol: Increased metoprolol effect or toxicity. Theophyllines: Increased theophylline effect or toxicity. Tricyclic antidepressants: Increased tricyclic antidepressant effect or toxicity. Troleandomycin: Increased frequency of cholestatic jaundice.

Drug Assesment ::

 Assessment/Interventions

• Obtain patient medical history, including drug history and any known allergies.
• Monitor blood glucose levels in patients with diabetes.
• If spotting or breakthrough bleeding continues past second month, notify physician.
• Do not administer oral contraceptives to induce withdrawal bleeding as test for pregnancy.

Drug Storage/Management ::

 Administration/Storage

• Give at same time each day. Efficacy depends on strict adherence to dosage schedule.
• May be given with or without food.

Drug Notes ::

 Patient/Family Education

• Advise patient to use additional method of birth control until after first week of administration in initial cycle.
• Advise patient what to do if dose is missed: (1) if missed 1, take when remember or take 2 the next day; (2) if missed 2, take 2 on 2 consecutive days; (3) if missed ³ 3, stop pills; (4) use alternative form of birth control in all cases.
• Advise patient to take multiple daily vitamin.
• Encourage patient who smokes to stop. Cardiovascular dysfunction and thromboembolic disease have been associated with use of oral contraceptives in patients who smoke.
• Advise patient that oral contraceptives may change the fit of rigid contact lenses.
• Caution patient to avoid prolonged exposure to sunlight, and to use sunscreen or wear protective clothing to avoid photosensitivity reaction.
• Advise patient to wait ³ 3 mo after discontinuing oral contraceptives to try to become pregnant.
• Caution patient that antibiotics may decrease effectiveness of oral contraceptives and to use a nonhormonal form of contraception while taking antibiotics and for 7 days after stopping antibiotics.
• Instruct patient to report symptoms of blood clots (eg, pain, numbness, shortness of breath, visual disturbances).
• Teach patient routine breast self-examination technique.
• Warn patient that side effects such as nausea and breakthrough bleeding are common at first.

Disclaimer ::

The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.